2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1705 Disruptive and nondisruptive TP53 mutations differentially impact clinical outcomes and inflammatory signaling in human AML

Ilias Sinanidis, MD, Megan Schmit-Diop, MD,PhD2, Adam Genda, MS3, Klara Noble-Orcutt, BS, MS4, Nuttavut Sumransub, MD5, Keith Cordner, MD6, Jeremy Allred, MD7, Mark B. Juckett, MD, MHCM8, Craig Eckfeldt, MD, PhD9, Naveen Premnath, MD10, Joseph Norton, D.O.11, Sean I. Tracy, MD, PhD12, Vidhyalakshmi Ramesh13, Andrew Nelson, MD, PhD14, Sophia Yohe, MD15, Veronika Bachanova, MD, PhD16, Zohar Sachs, MD, PhD17
1 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
2 Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States
3 Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, Minnesota, United States
4 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
5 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
6 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
7 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
8 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
9 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
10 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
11 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
12 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
13 Clinical Informatics, University of Minnesota, Minneapolis, Minnesota, United States
14 Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, Minnesota, United States
15 Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, Minnesota, United States
16 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
17 Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, Minnesota, United States, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Introduction: Acute myeloid leukemia (AML) with TP53 mutations (TP53m) is an adverse-risk group. TP53m myelodysplastic syndrome (MDS) carries clinical outcomes that are indistinguishable from those of TP53m AML across the literature. TP53m exhibit loss-of-function (LOF), dominant-negative effect, or gain-of-function (GOF), which are associated with variations in disease severity in preclinical models. The impact of these mutation categories on clinical outcomes in human AML has not been demonstrated largely because patients harbor many more TP53m than have been characterized. Recently, pathogenic TP53m have been functionally classified according to predicted protein function as disruptive (truncation or alteration in polarity in L2-L3 regions, zinc, or hydrogen bond) and nondisruptive (Poeta 2007; Caponio 2024). We investigated whether TP53m class impacts clinical outcomes and disease biology in human AML.

Methods: Kaplan-Meier analyses (KM) were censored at 24 months (mo), pairwise comparisons were adjusted using Holm multiple testing correction, and multivariable analyses (MVA) were adjusted for age, number of TP53m, and diagnosis (MDS/other, AML, relapse/progression) at the time of TP53m detection.

Results: Among AML patients with TP53m (n=150), median overall survival (mOS) of patients with TP53m detected prior to AML diagnosis (n=33; 29 MDS, 4 other) was inferior to those with TP53m detected at the time of AML diagnosis (n=79; mOS from AML diagnosis: 1.9 vs 6.1 mo, p=0.04). Patients who developed a TP53m later in their disease course (n=38) had the highest mOS (14.9 mo since AML diagnosis, p<0.001). Time from TP53m to AML diagnosis is an independent risk factor for death by MVA (HR=1.05 per mo, p<0.001). Accordingly, mOS from first detection of TP53m (OS-TP53) was similar among the three groups (11.7, 6.1, 6.4 mo; p=0.6). OS-TP53 of patients with GOF (n=18) and truncating (prototypical LOF; n=19) TP53m were similar (7.8 and 5.6 mo, respectively, p=0.3). However, OS-TP53 was superior in monoallelic (n=31) vs biallelic (n=119) TP53m AML (12.3 vs 5.9 mo; p=0.02), suggesting that retaining wild-type (WT) p53 protein improves outcomes.

Therefore, we defined three groups based on p53 function: biallelic TP53m with predicted residual function (pRF: at least one non-disruptive TP53m, n=65), predicted LOF (pLOF: only disruptive TP53m, n=54), and WT-retained (monoallelic TP53m). The pLOF group showed significantly inferior OS-TP53 relative to the pRF group (3.7 vs. 8.4 mo, p=0.04). MVA Cox validated that pLOF independently associated with worse OS-TP53 compared to pRF (HR=1.67, p=0.02). The OS-TP53 of WT-retained and pRF groups were comparable (HR=0.76, p=0.3). Among patients who received hematopoietic stem cell transplant (HSCT), OS from time of HSCT was similar between pLOF (n=10) and pRF (n=19) groups (p=0.4). In contrast, among patients who did not undergo HSCT, pLOF group (n=44) demonstrated inferior OS-TP53 compared with pRF group (n=46, mOS-TP53 of 3.0 vs 5.9 mo, p=0.041, MVA; HR=1.64, p=0.041); similar to the WT-retained group (n=23, mOS-TP53=8 mo, p=0.1). These data indicate that TP53m type impacts clinical outcomes but also that these effects can be overcome by HSCT.

As TP53m AML is known to be inflammatory and immune-suppressive, and HSCT constitutes an immune-based therapy that overcomes the effects of TP53 mutation class, we used CyTOF to measure levels of inflammatory signaling proteins in leukemia stem cells of TP53 WT (n=22) and mutant (n=14 disruptive, n=10 nondisruptive) primary AML samples. TP53m stem cells displayed higher levels of inflammation-associated signaling molecules (phosphorylated NFkB, p38, MAPKAPK2, STAT1, and STAT5; p<0.05). Interestingly, stem cells among nondisruptive TP53m samples expressed higher levels of phosphorylated NFkB and STAT5 (p<0.05) relative to stem cells of disruptive TP53m samples. Single-cell RNA sequencing of these samples revealed that stem cells with nondisruptive TP53m are enriched in signatures of inflammation and T cell suppression relative to those with disruptive TP53m. These data suggest that nondisruptive mutations, which retain some p53 function, may exert an impact on inflammation, which may correlate with their clinical outcomes.

Conclusions: TP53m type, defined by status of residual p53 function, impacts clinical outcomes in AML. Residual p53 function is correlated with altered inflammatory signaling, suggesting possible therapeutic targets in this TP53m AML.
Ilias Sinanidis, MD: No relevant conflicts of interest to declare.